-
公开(公告)号：US07901670B2
公开(公告)日：2011-03-08
申请号：US10581597
申请日：2004-12-04
申请人： Ji Sook Park , Jong Sang Chung , Min Ji Baek , Jee Won Ahn , Ki Wan Kim , Hyung Ki Park , Dong Eok Lee , Myung Suk Oh
发明人： Ji Sook Park , Jong Sang Chung , Min Ji Baek , Jee Won Ahn , Ki Wan Kim , Hyung Ki Park , Dong Eok Lee , Myung Suk Oh
CPC分类号： C07K14/565 , C12P21/02
摘要： Provided is a process for purifying human interferon beta from a recombinant human interferon beta-containing culture comprising performing affinity chromatography and cation exchange chromatography, wherein the affinity chromatography includes: adsorbing the interferon beta-containing culture to an equilibrated affinity chromatography column, followed by washing with an equilibration buffer solution; washing the column with a washing buffer solution A of pH 6.5-7.5 containing 30-60 wt % of propylene glycol and a washing buffer solution B of pH 6.5-7.5 containing 10-30 wt % of propylene glycol and 1-2M NaCl; and eluting a human interferon beta-containing fraction with a buffer solution of pH 6.5-7.5 containing 40-60 wt % of propylene glycol and 1-2M NaCl.
摘要翻译： 提供了一种从重组人类干扰素β的培养物中纯化人类干扰素β的方法，包括进行亲和层析和阳离子交换层析，其中亲和层析包括：将含干扰素β的培养物吸附到平衡的亲和色谱柱上，然后洗涤 用平衡缓冲溶液; 用含有30-60重量％丙二醇的pH 6.5-7.5的洗涤缓冲溶液A和pH6.5-7.5的洗涤缓冲液B洗涤柱子，其中含有10-30重量％的丙二醇和1-2M的NaCl; 并用含有40-60重量％丙二醇和1-2M NaCl的pH 6.5-7.5的缓冲溶液洗脱人类含有干扰素β的级分。
-
2.发明授权Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform 失效糖基化的人粒细胞集落刺激因子（G-CSF）同种型公开(公告)号：US07344858B2
公开(公告)日：2008-03-18
申请号：US10651395
申请日：2003-08-29
申请人： Eun Jung Lee , Hyun Seok Kim , Jong Sang Chung , Ki Wan Kim , Yeon Hyang Kim , Hyune Soo Lee , Hyung Kon Koh , Myung Suk Oh
发明人： Eun Jung Lee , Hyun Seok Kim , Jong Sang Chung , Ki Wan Kim , Yeon Hyang Kim , Hyune Soo Lee , Hyung Kon Koh , Myung Suk Oh
IPC分类号： C12N15/27 , C12N15/66 , C07K14/535 , A61K38/18
CPC分类号： C07K14/535 , A61K38/00
摘要： Disclosed are human G-CSF isoforms having a modified amino acid sequence containing a glycosylation sequence Asn-X-Ser/Thr (N-X-S/T) at one or more specific amino acid positions according to the present invention, genes encoding the human G-CSF isoforms, and expression vectors carrying the genes, eukaryotic cells transformed or transfected with the expression vectors. Also, the present invention discloses a method of preparing a glycosylated human G-CSF isoform, comprising the steps of culturing the transformant or transfectant and isolating a glycosylated human G-CSF isoform from the culture supernatant or cell lysates, a human G-CSF isoform prepared by the method, and a pharmaceutical composition comprising the human G-CSF isoform.
摘要翻译： 公开了具有在本发明的一个或多个特定氨基酸位置上含有糖基化序列Asn-X-Ser / Thr（NXS / T）的修饰氨基酸序列的人G-CSF同种型，编码人G-CSF的基因 同种型和携带基因的表达载体，用表达载体转化或转染的真核细胞。 此外，本发明公开了一种制备糖基化的人G-CSF同工型的方法，其包括培养转化体或转染子并从培养上清或细胞裂解物，人G-CSF同工型分离糖基化的人G-CSF同种型的步骤 通过该方法制备，以及包含人G-CSF同种型的药物组合物。
-
公开(公告)号：US07780960B2
公开(公告)日：2010-08-24
申请号：US10581602
申请日：2004-12-04
申请人： Ji Sook Park , Jong Sang Chung , Min Ji Baek , Jee Won Ahn , Ki Wan Kim , Hyung Ki Park , Dong Eok Lee , Myung Suk Oh
发明人： Ji Sook Park , Jong Sang Chung , Min Ji Baek , Jee Won Ahn , Ki Wan Kim , Hyung Ki Park , Dong Eok Lee , Myung Suk Oh
CPC分类号： C07K14/565 , C07K5/06139
摘要： Provided is a process for purifying human interferon beta from a recombinant human interferon beta-containing culture comprising performing affinity chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC), wherein the affinity chromatography includes: adsorbing the interferon beta-containing culture to an equilibrated affinity chromatography column, followed by washing with an equilibration buffer solution; washing the column with a washing buffer solution A of pH 6.5-7.5 containing 30-60 wt % of propylene glycol and a washing buffer solution B of pH 6.5-7.5 containing 10-30 wt % of propylene glycol and 1-2M NaCl; and eluting a human interferon beta-containing fraction with a buffer solution of pH 6.5-7.5 containing 40-60 wt % of propylene glycol and 1-2M NaCl.
摘要翻译： 提供了一种从重组人类干扰素β培养物中纯化人类干扰素β的方法，包括进行亲和层析和反相高效液相色谱（RP-HPLC），其中亲和层析包括：吸附含有干扰素β的培养物 平衡的亲和层析柱，然后用平衡缓冲液洗涤; 用含有30-60重量％丙二醇的pH 6.5-7.5的洗涤缓冲溶液A和pH6.5-7.5的洗涤缓冲液B洗涤柱子，其中含有10-30重量％的丙二醇和1-2M的NaCl; 并用含有40-60重量％丙二醇和1-2M NaCl的pH 6.5-7.5的缓冲溶液洗脱人类含有干扰素β的级分。
-
4.发明申请公开(公告)号：US20090221037A1
公开(公告)日：2009-09-03
申请号：US10433508
申请日：2001-12-10
申请人： Dong-Eok Lee , Myung-Suk Oh , Ki-Wan Kim , Bo-Sup Chung , Byung-Jhip Ha , Ji-Sook Park
发明人： Dong-Eok Lee , Myung-Suk Oh , Ki-Wan Kim , Bo-Sup Chung , Byung-Jhip Ha , Ji-Sook Park
IPC分类号： C12P21/06 , C07K14/505 , C07H21/04
CPC分类号： C07K14/505 , C07K14/59 , C07K2319/00
摘要： The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.
摘要翻译： 本发明涉及将人促红细胞生成素（EPO）的羧基末端与人绒毛膜促性腺激素（HCG）的β亚基的羧基末端肽片段与编码融合蛋白质的DNA融合的融合蛋白质， 融合蛋白的制备。 融合蛋白具有增强的红细胞生成素的体内活性。
-
公开(公告)号：US07098318B2
公开(公告)日：2006-08-29
申请号：US10230454
申请日：2002-08-29
申请人： Dong-Eok Lee , Myung-Suk Oh , Bo-Sup Chung , Ji-Sook Park , Ki-Wan Kim
发明人： Dong-Eok Lee , Myung-Suk Oh , Bo-Sup Chung , Ji-Sook Park , Ki-Wan Kim
CPC分类号： C07K14/524 , A61K38/00 , C07K14/505 , C07K2319/00
摘要： The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.
-
公开(公告)号：US07091326B2
公开(公告)日：2006-08-15
申请号：US10196183
申请日：2002-07-17
申请人： Dong-eok Lee , Myung-suk Oh , Ki-wan Kim , Bo-sup Chung , Ji-sook Park
发明人： Dong-eok Lee , Myung-suk Oh , Ki-wan Kim , Bo-sup Chung , Ji-sook Park
IPC分类号： C07K14/59 , C07K14/505 , C12N15/00 , C12N15/62
CPC分类号： C12N15/62 , A61K38/00 , C07K14/505 , C07K14/59 , C07K2319/00 , C07K2319/75
摘要： Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) β subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.
-
7.发明授权公开(公告)号：US08008454B2
公开(公告)日：2011-08-30
申请号：US10433508
申请日：2001-12-10
申请人： Dong-Eok Lee , Myung-Suk Oh , Ki-Wan Kim , Bo-Sup Chung , Byung-Jhip Ha , Ji-Sook Park
发明人： Dong-Eok Lee , Myung-Suk Oh , Ki-Wan Kim , Bo-Sup Chung , Byung-Jhip Ha , Ji-Sook Park
CPC分类号： C07K14/505 , C07K14/59 , C07K2319/00
摘要： The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.
摘要翻译： 本发明涉及融合蛋白，其中人促红细胞生成素（EPO）的羧基末端与羧基末端肽片段“ 人绒毛膜促性腺激素（HCG）的亚单位，编码融合蛋白的DNA，以及融合蛋白的制备方法。 融合蛋白具有增强的红细胞生成素的体内活性。
-
公开(公告)号：US07311903B2
公开(公告)日：2007-12-25
申请号：US10653350
申请日：2003-09-02
申请人： Eun Jung Lee , Hyung Ki Park , Hyun Seok Kim , Ji Sook Park , Yeon Hyang Kim , Hyune Soo Lee , Hyung Kon Koh , Myung Suk Oh
发明人： Eun Jung Lee , Hyung Ki Park , Hyun Seok Kim , Ji Sook Park , Yeon Hyang Kim , Hyune Soo Lee , Hyung Kon Koh , Myung Suk Oh
CPC分类号： C07K14/56
摘要： The present invention relates to an amino acid-modified human interferon alpha isoform having at least one of the Asn-Xaa-Ser/Thr (N-X-S/T) sequence formed at a specific site so that glycosylation takes place at this site and a gene encoding the same, an expression vector comprising the gene, and a method for producing glycosylated human interferon alpha isoform by transforming or transfecting an eukaryotic cell with the expression vector, culturing the transfected or transformed cell and isolating the glycosylated human interferon alpha isoform from the culture, the glycosylated human interferon alpha isoform produced therefrom and a pharmaceutical composition comprising the same.
摘要翻译： 本发明涉及具有在特定部位形成的至少一种Asn-Xaa-Ser / Thr（NXS / T）序列的氨基酸修饰的人类干扰素α同种型，使得在该位点发生糖基化，并编码基因 相同的包含该基因的表达载体和通过用表达载体转化或转染真核细胞来产生糖基化的人干扰素α同种型的方法，培养转染或转化的细胞并从培养物中分离糖基化的人干扰素α同种型， 由其制备的糖基化的人干扰素α同种型和包含其的药物组合物。
-
公开(公告)号：US20050019871A1
公开(公告)日：2005-01-27
申请号：US10653350
申请日：2003-09-02
申请人： Eun Jung Lee , Hyung Park , Hyun Seok Kim , Ji Sook Park , Yeon Hyang Kim , Hyune Soo Lee , Hyung Kon Koh , Myung Suk Oh
发明人： Eun Jung Lee , Hyung Park , Hyun Seok Kim , Ji Sook Park , Yeon Hyang Kim , Hyune Soo Lee , Hyung Kon Koh , Myung Suk Oh
CPC分类号： C07K14/56
摘要： The present invention relates to an amino acid-modified human interferon alpha isoform having at least one of the Asn-Xaa-Ser/Thr (N-X-S/T) sequence formed at a specific site so that glycosylation takes place at this site and a gene encoding the same, an expression vector comprising the gene, and a method for producing glycosylated human interferon alpha isoform by transforming or transfecting an eukaryotic cell with the expression vector, culturing the transfected or transformed cell and isolating the glycosylated human interferon alpha isoform from the culture, the glycosylated human interferon alpha isoform produced therefrom and a pharmaceutical composition comprising the same.
摘要翻译： 本发明涉及具有在特定部位形成的至少一种Asn-Xaa-Ser / Thr（NXS / T）序列的氨基酸修饰的人类干扰素α同种型，使得在该位点发生糖基化，并编码基因 相同的包含该基因的表达载体和通过用表达载体转化或转染真核细胞来产生糖基化的人干扰素α同种型的方法，培养转染或转化的细胞并从培养物中分离糖基化的人干扰素α同种型， 由其制备的糖基化的人干扰素α同种型和包含其的药物组合物。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.016 秒)
